Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The impressive growth was driven by only five products
Thursday 08 Jun 2017 Author: Lisa-Marie Janes

This was how much the immuno-oncology market was worth in 2016 according to FinnCap as pharmaceutical companies aim to use the immune system to fight cancer.

The immuno-oncology market increased in value by 159% over 2015 - driven by only five products. One of these was AstraZeneca’s (AZN) lung cancer drug Imfinzi which recently dominated headlines after the firm revealed the drug significantly reduced the risk of the disease intensifying or leading to death.

‹ Previous2017-06-08Next ›